Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amplify Transformational Data Sharing ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.78 (market cap $29.60B), while Amplify Transformational Data Sharing ETF trades at $60.17. The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BLOK | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $74.10 |
52-Week Low | $205.48 | $47.36 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
BLOK trades at $60.00, up 1.56% today, but faces bearish technical signals with 14 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal downward pressure. Recent institutional activity shows Dynamic Advisor Solutions reduced its position by 81.1% in Q2 2026. The ETF focuses on transformational data sharing companies with exposure to AI infrastructure and blockchain economy participants.
The outlook remains cautious given bearish technical indicators and institutional selling. Investment opportunity exists in the ETF's diversified exposure to data sharing and AI infrastructure growth, but risks include sector volatility and competitive ETF pressure. The dividend of $0.08 scheduled for June 2026 provides minor income support amid uncertain market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
